Inverness, GE Capital, Biosite, Sigma-Aldrich, Agilent, Becton Dickinson, bioMerieux, Affymetrix, Gene Logic, Invitrogen, Luminex, Johns Hopkins, Sequenom | GenomeWeb
Inverness Gets Financial Backing from GE Capital, UBS in Biosite Bid
 
Biosite said last week that Inverness Medical Innovations plans to buy the company with financial backing from General Electric Capital Corporation and UBS Loan Finance and Securities.
 
In a revised commitment letter Inverness sent to Biosite and disclosed last week, Biosite said that GECC and UBSS would loan Inverness $1.3 billion. GECC will provide 40 percent of the amount and UBSS will drum up the 60 percent balance.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."